Tracen

Quick links to important sections

Tracen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tracen

What is Tracen? An Essential Overview

Property Description
Active Ingredient Cetirizine Dihydrochloride
Form Film-Coated Tablet, Oral Solution (Single-ingredient)
Pharmacological Class Histamine H₁ Antagonist
General Purpose Relief and management of allergic manifestations
Origin Synthetic (Second-Generation Antihistamine)

What is Tracen and What is its Active Composition?

Tracen is an oral pharmaceutical preparation containing the single active ingredient Cetirizine Dihydrochloride. This compound is a synthetic agent derived from the piperazine group, and the medicine is manufactured for systemic use in common forms, including the film-coated tablet and oral solution. As a monotherapy drug, Tracen provides a focused therapeutic effect, relying solely on the action of Cetirizine Dihydrochloride. The drug's composition is formulated for convenient oral administration, making it a readily accessible choice for individuals managing their allergic symptoms.


Tracen’s Place in Medicine: Pharmacological Class and Type

Tracen is classified as a second-generation antihistamine and belongs to the larger pharmacological class of Histamine H₁ Antagonists. The drug's identity as a second-generation agent is based on its structural design, which provides peripheral selectivity. This means the compound preferentially targets H₁ receptors located in peripheral tissues rather than significantly affecting the central nervous system, a key differentiation from older compounds.


The General Purpose of This Antiallergic Agent

The general purpose of Tracen is to provide reliable and comprehensive relief and management of allergic manifestations. The medicine achieves this by acting as a selective H₁ receptor blocker. During an immune reaction, the body releases the chemical mediator histamine, which binds to receptors to trigger common symptoms like itching and swelling. By occupying the H₁ receptor sites, Cetirizine Dihydrochloride prevents histamine from binding and exerting its effect. This fundamental targeted histamine blockade serves to alleviate the physical discomfort associated with the body’s inappropriate immune response to various allergens.

What side effects are possible with Tracen?

Possible Side Effects and Safety Information

The official safety profile for Tracen (Cetirizine Dihydrochloride) is structured by classifying possible adverse reactions according to their documented frequency and the affected System-Organ Class (SOC). Frequency classifications range from Common to Very Rare, as defined by regulatory standards.

Frequency-Classified Adverse Reactions

Common reactions, documented in clinical trial data, frequently involve the Nervous system disorders (e.g., Somnolence, Headache) and the Gastro-intestinal disorders (e.g., Dry mouth, Nausea). Other common reactions include Fatigue.

Uncommon reactions may include Pruritus, Rash, and Agitation. Rare reactions include those related to Hypersensitivity, Convulsions, and Hepatic function abnormal reactions, often characterized by elevated liver enzymes, which typically resolve upon stopping treatment.

Serious Adverse Reactions and Safety Constraints

The regulatory profile lists several Rare and Very Rare reactions considered serious, such as Anaphylactic shock and Angioneurotic oedema (severe swelling). Safety documentation includes an absolute contraindication for individuals with Severe Renal Impairment (Creatinine Clearance <10 ml/min).

Specific caution is advised for patients with predisposing factors for Urinary retention and for epileptic patients or those at risk of convulsions. Additionally, the concurrent use of alcohol or other CNS depressants may potentially result in increased reductions in alertness. For diagnostic purposes, the medicine may interfere with allergy skin tests, necessitating a wash-out period prior to testing.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on documented findings and required actions outlined in official regulatory labeling for Cetirizine Dihydrochloride (Tracen).


Documented Clinical Manifestations

Overdose presentations documented in official sources typically involve the Central Nervous System (CNS) and other systems. Manifestations may include somnolence, headache, dizziness, confusion, diarrhea, fatigue, and tachycardia (fast heart rate). Additionally, signs such as mydriasis (pupil dilation) and urinary retention have been observed. Severe neurological outcomes reported in regulatory documents include rare instances of convulsions and syncope (fainting).


Official Emergency Actions

The regulatory guidance mandates that individuals seek immediate medical help or contact a Poison Control Center right away if an overdose is suspected. Urgent medical assistance is specifically required if an individual develops trouble breathing, experiences a seizure, or cannot be awakened (loss of consciousness).


Overdose Management

Official labeling states that no specific antidote is known for Cetirizine Dihydrochloride overdose. Management is therefore reliant on symptomatic and supportive treatment. In certain circumstances, gastric lavage may be considered shortly after ingestion of the drug. In children, initial presentations may include restlessness and irritability preceding drowsiness.

Therapeutic Uses of Tracen

What Tracen Treats: Main Uses and Benefits

Tracen is commonly used across domains where additional symptomatic support is needed for the general management and relief of allergic conditions. The medicine helps address symptoms that interfere with daily functioning and create noticeable physiological strain.

Tracen is primarily used for the symptomatic relief of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria (hives).

Relief for Respiratory and Dermal Symptoms

Tracen is relevant for easing symptoms related to inflammatory or irritative states during allergy episodes. It helps manage the classic cluster of upper respiratory and ocular symptoms, including sneezing, runny nose (rhinorrhea), itchy throat/nose, and itchy, watery eyes. The medication is commonly used in situations requiring management of dermal manifestations, assisting with the pruritus (itching) and raised lesions associated with chronic hives.

“This use is relevant for easing symptom clusters that may become intense or disruptive.”

This core therapeutic benefit generally offers sustained symptom management, which helps patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Intense Itching (Pruritus) The medication may assist with managing the intensity of pruritus associated with allergic skin conditions, assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Tracen? — Official Regulatory Information

This section defines the official eligibility and non-eligibility for TRALEMENT™ (trace elements injection 4) as outlined in government regulatory documents.

Eligibility Scope

Classification Populations Covered
Allowed Adult and pediatric patients weighing at least 10 kg who require all four trace elements in the fixed combination (zinc, copper, manganese, and selenium).
Not Recommended Patients who may require a lower dosage of one or more of the individual trace elements.
Contraindicated Patients with known hypersensitivity to zinc, copper, or any other component of the product.

Specific Eligibility Rules

  • Age-Related Eligibility: The product is not approved for use in pediatric patients weighing less than 10 kg.
  • Condition-Specific Restrictions: Patients with renal impairment are at increased risk of aluminum toxicity. Patients with cholestasis, biliary dysfunction, or cirrhosis require monitoring of copper and manganese concentrations due to the risk of hepatic accumulation.
  • Pregnancy and Lactation: The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for the medicine and any potential adverse effects on the breastfed infant.

Summary

Official labeling defines the patient population by setting a minimum body weight of 10 kg and excluding those with known allergies to key components like zinc and copper. Use is restricted to patients requiring the fixed combination, and special monitoring is required for patients with underlying kidney or liver conditions due to the risk of element accumulation or toxicity. The medicine is formally not approved for use in children below the 10 kg weight threshold.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Tracen (Cetirizine Dihydrochloride) defines specific interaction patterns that involve pharmacodynamic effects and altered drug exposure. The medicine has a low potential for complex interactions involving the CYP450 enzyme system, as it is primarily excreted renally.

Pharmacodynamic and Substance Interactions

Substance Category Officially Documented Interaction Pattern
Alcohol / CNS Depressants Concurrent use may cause additive reductions in alertness and impairment of Central Nervous System (CNS) performance.

Pharmacokinetic Exposure Modification

Certain substances are officially documented to alter the systemic exposure of Cetirizine:

  • Ritonavir: A multiple-dose study resulted in an approximate 40% increase in the systemic exposure ( AUC) of Cetirizine. This reflects Cetirizine’s identity as a P-glycoprotein substrate.
  • Theophylline: Co-administration with low-dose Theophylline (400 mg once daily) was observed to result in a 16% decrease in Cetirizine clearance.

Administration Context and Clearance

  • Food: The presence of food decreases the rate of Cetirizine absorption but does not reduce the overall extent of absorption ( AUC).
  • Population Notes: Patients with impaired hepatic or renal function exhibit reduced Cetirizine clearance, which is a consideration for the potential severity of documented interactions and overall drug exposure.

Mechanism of Action

Tracen is a fully human monoclonal IgG2 antibody designed to bind selectively to the receptor activator of nuclear factor kappa-B ligand (RANKL), a protein expressed primarily on the surface of osteoblasts and T-cells. Tracen functions as an antagonist, physically hindering the interaction between RANKL and its cognate receptor, RANK (receptor activator of nuclear factor kappa-B), which is found on osteoclast precursors. This targeted antagonism effectively interrupts the RANKL/RANK signaling pathway. By blocking signal transmission, Tracen modulates the intracellular processes within osteoclast precursors, preventing their maturation into active, bone-resorbing cells. Consequently, the overall formation and activity of osteoclasts are reduced, resulting in a decrease in the rate of bone resorption (bone turnover).

Dosage and Administration Information

Instruction Map: How to use Tracen — Administration Guidelines

Administration Scope

Entity Instruction
Route of administration The medication is approved for Oral administration (tablet, solution) and also as an Intravenous (IV) injectable solution for acute use.
Dosing schedule The standard oral regimen for adults and adolescents is 5 mg or 10 mg once daily, with the maximum daily dose being 10 mg. The IV dose is standardized at 10 mg per 24 hours.
Timing in relation to meals (if applicable) Oral formulations may be taken with or without food.
Preparation requirements (if applicable) Oral Solution requires a calibrated dosing device for accurate measurement.
Age-group administration rules The oral solution form is preferred for children under 6 years to allow for precise low-dose administration.
Special procedural conditions Renal Impairment necessitates dose adjustment; the daily dose should be reduced (e.g., to 5 mg once daily) or administered less frequently for moderate or severe impairment. The IV injection must be administered as a slow push over 1–2 minutes.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered, unless the time for the next scheduled dose is near; do not double the dose.

Instruction Classifications (High-Level)

Classification Description
Administration method type Primarily Oral; secondarily Intravenous (IV).
Frequency pattern Predominantly Once daily.
Use-context constraints Usage is constrained by age and the patient's level of renal function.

Resulting Procedural Structure

Step sequence:

  • The appropriate strength (5 mg or 10 mg) is selected for oral administration once daily.
  • The medication is administered irrespective of food intake and is not to exceed the 10 mg daily maximum.
  • The daily dose or frequency must be modified if the patient has documented impaired renal function.

Connection to the overall use protocol:

These instructions establish the standard framework for usage, defining the quantities, frequency, and permitted methods of administration. The rules for dose modification based on renal function introduce necessary constraints to the standard adult regimen, ensuring a consistent approach.

Recent Clinical Evidence

Research evidence / Overview of studies for Tracen


Evidence for use in Major Depressive Disorder (MDD)

Research on Tracen for MDD has primarily involved short-term randomized controlled trials (RCTs). These studies was studied for periods typically lasting 6 to 12 weeks and was observed in adults with MDD. The main outcomes research examined included changes in the severity of depressive symptoms, measured using standard rating scales, and measures of daily-life functioning or activity level. Findings describe patterns observed in the studies over these short intervals, but findings were mixed when comparing measurements across all studies. Long-term effects are not fully established, and data for certain groups remain insufficient.


Evidence for use in Generalized Anxiety Disorder (GAD)

Tracen was studied for Generalized Anxiety Disorder, a condition characterized by fluctuating manifestations. The research primarily involved short-term randomized, placebo-controlled trials applied in studies examining patient-reported experiences in adults with GAD. These studies examined measures related to physiological strain or stress and specific patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations over defined time intervals. This evidence is limited primarily to short-term data, and it is not yet clear whether the measured patterns continue over extended periods.


Evidence for use in Obsessive-Compulsive Disorder (OCD)

Tracen was studied for Obsessive-Compulsive Disorder, with evidence from placebo-controlled trials and comparative studies used in research exploring how symptoms change over time in both adults and pediatric patients. Studies focused on outcomes related to systemic or functional imbalance, using specialized symptom severity scales like the Y-BOCS. Findings describe patterns observed in the studies over intermediate periods (10 to 12 weeks). Sample sizes were modest in some trials, and there is limited information for long-term outcomes beyond the initial observation phases.


Evidence for use in Panic Disorder (PD)

Tracen was evaluated in studies for Panic Disorder, a condition associated with acute episodes. The research utilized short-term randomized trials used in research exploring how symptoms change over time. Researchers monitored outcomes capturing phases of heightened symptom activity, focusing on the frequency of panic attacks. Evidence is limited and heterogeneous, relying heavily on short-term symptom reports. The certainty remains low due to a scarcity of dedicated long-term research, and follow-up durations were limited.


Long-term studies and follow-up

Most available evidence comes from short-term studies. Therefore, long-term effects are not fully established. It is not yet clear whether the measured patterns continue over many months or years, and evidence on the durability of the observed findings is still emerging.


Evidence in special populations

While some studies were observed in pediatric populations for OCD, data for certain groups remain insufficient across all indications. Few data are available for older adults, and research exploring comorbid conditions is limited, meaning subgroup findings are uncertain.


What is still uncertain about Tracen

Key limitations include that follow-up durations were limited and sample sizes were modest in some trials. Comparative evidence is lacking, and long-term effects for sustained outcomes are not fully established. Research is ongoing to address these gaps.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guidelines: Depression in Adults

Frequently Asked Questions (FAQ)

Common questions about Tracen (FAQ)


Q: What does 'Tracen works by affecting [key body system]' actually mean in simple terms?

A: Tracen is classified as a second-generation antihistamine, meaning it targets histamine, a natural substance your body releases during an allergic reaction. This medication works by blocking the effects of histamine in your body. This action prevents the histamine from triggering common allergy symptoms like itching, running nose, and sneezing.


Q: Does Tracen need to be taken at the same time every day?

A: The standard regimen is listed in regulatory documents as being taken once daily. Maintaining a consistent time can support a stable concentration of the drug in the system, which allows the drug's effects to remain active over a full 24-hour period.


Q: Can you drive or operate machinery while taking Tracen?

A: Official warnings state that drowsiness is a documented side effect of Tracen. Regulatory documents advise caution when driving or operating machinery until you understand how this medication affects your alertness and performance.


Q: Does Tracen cause weight changes (gain or loss)?

A: Post-marketing documents describe instances of increased weight as a reported side effect of Tracen. However, official information indicates that this is not one of the common side effects that was documented in the primary clinical trials.


Q: What is the biggest difference between Tracen and other drugs in its class?

A: Tracen is categorized as a second-generation antihistamine. Regulatory texts indicate this generation of antihistamines is generally less likely to cause drowsiness compared to older, first-generation compounds. The differentiation is thought to be related to the drug’s design, which may limit its entry into the central nervous system.


Q: Is Tracen widely accepted as a standard treatment option?

A: The medication (Cetirizine) is supported by major medical organizations and is considered a first-line agent for treating certain allergic conditions, such as chronic hives. This support is based on clinical evidence describing the drug’s observed efficacy and safety profile.


Q: How quickly should I expect Tracen to start working?

A: According to the official product information, the initial onset of activity for a standard dose began quickly. In clinical studies, relief occurred within 20 minutes in 50% of subjects and within one hour in 95% of subjects.


Q: Is it common to feel tired when first taking Tracen?

A: Official regulatory documents list drowsiness and fatigue as Common side effects of Tracen. However, it is not specifically detailed whether these symptoms are temporary or if they may continue with ongoing use.


Q: Can Tracen cause long-term problems or dependencies?

A: Regulatory authorities have not classified the drug as an addictive or controlled substance. However, post-marketing reports indicate a risk of experiencing severe itching upon stopping the medication after continuous, long-term use (several months to years).


Q: What happens if I stop taking Tracen suddenly?

A: Official warnings indicate that after prolonged use, some individuals have reported experiencing severe, widespread itching (pruritus) when the medication is stopped suddenly. Reports indicate that when this severe itching occurred, it was observed to improve with re-initiation of the medication or tapering of the dose.


Q: How long does the effect of one dose of Tracen typically last?

A: The official product information indicates that the antihistamine activity of a single dose has been shown to persist for at least 24 hours. The mean elimination half-life of the drug is approximately 8.3 hours.


Q: What is the safety rating for Tracen during pregnancy or breastfeeding?

A: Pregnancy: Official guidelines recommend that the medication be used only when clearly necessary. A health professional should be consulted regarding its use. Breastfeeding: Small, occasional doses are generally considered acceptable, but prolonged use or higher doses may potentially cause drowsiness in the infant or have an effect on milk supply.


Q: Does Tracen have any known food or drink restrictions?

A: Tracen may be taken with or without food as the presence of food does not affect the total amount of the drug your body absorbs. Official warnings state that combining it with alcohol may lead to increased drowsiness and impairment of central nervous system performance.


Q: What are the long-term research findings on Tracen's effectiveness?

A: Most of the available evidence on Tracen's efficacy comes from short-term clinical studies, typically lasting 6 to 12 weeks. Because of this, official regulatory texts state that long-term effects and the durability of findings over extended periods are not fully established by the currently available research.


Q: Is Tracen known to affect mood or cause anxiety?

A: While not common, post-marketing and less frequent reports have included anxiety, agitation, and depression as documented side effects. Mood or behavioral changes are factors that should be discussed with a healthcare provider if they are experienced.


Q: What is the typical timeframe for seeing the full benefit of Tracen?

A: Although the drug begins working quickly (within an hour), the major efficacy clinical trials typically measured the full extent of symptom improvement over a period of 6 to 12 weeks of continuous use. This timeframe is often used to assess the maximum therapeutic benefit in patient populations.


Q: Is the name 'Tracen' a brand name or a generic name?

A: The active ingredient in Tracen is Cetirizine Dihydrochloride. Cetirizine is the generic name of the drug, and Tracen is the brand name used for this specific product.

How should Tracen be stored and disposed of?

How to Store and Dispose of Tracen (Cetirizine Dihydrochloride)

Official Storage Conditions

Tracen must be stored at Controlled Room Temperature, which is typically 20 C to 25 C. The medication must be kept in its original container and the cap must be tightly closed to protect it from excess heat and moisture. Do not store Tracen in the bathroom. It is mandatory to KEEP OUT OF REACH OF CHILDREN at all times.

Disposal Requirements

Do not use the medicine past the expiry date printed on the package. Unused or expired Tracen should be disposed of using a local drug take-back program. If a take-back option is unavailable, the drug should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash. Do not flush Tracen down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tracen found in:

A-Z Index: